Diego J. Maselli MD, FCCP ATSF retweeted
ECCMID 2026
No induction of resistance over 6 months with monoclonal antibody therapy against pseudomonas in bronchiectasis
Encouraging beneficial changes to the microbiome too
Encouraging early results presented by @beccahull_
Diego J. Maselli MD, FCCP ATSF retweeted
Characterisation of the eosinophilic endotype of bronchiectasis
We use a novel method of quantifying eosinophil granule proteins in sputum: Eosinophilic inflammation is present in bronchiectasis but poorly associated with blood eosinophils
@EMBARCnetwork
thorax.bmj.com/content/early…
Diego J. Maselli MD, FCCP ATSF retweeted
Time to get your heart racing (literally)! Deep dive into cardiogenic shock at 945 am 🚑💔
#CHEST2025
#CHESTSoMe
@sfaiz212 @KhasterDinh @PatelMaulin17
Diego J. Maselli MD, FCCP ATSF retweeted
📣 Semana ALAT del Pulmón 2025
🫁 “Desafiando los hechos”
📌 Martes 23/09 – 18:05 h (MX)
👤 Ponente: 🇺🇸 Diego Maselli C.
🎙 Tema: PRO: Reducir la dosis de biológicos
💻 Virtual y sin costo ➡️ bit.ly/42cUuQo
#SemanaALATdelPulmón
Diego J. Maselli MD, FCCP ATSF retweeted
Can emphysema be repaired? What started as a bold idea from Steve Rennard led to the creation of ASTE (Advanced Study to Treat Emphysema). Our first publication is out, laying the groundwork for the approach we’re taking to tackle this challenge.
#cureCOPD
🔗Link here:
atsjournals.org/doi/abs/10.1…
Diego J. Maselli MD, FCCP ATSF retweeted
Look what just appeared online as part of the ERS congress programme for September 👀
Can't wait to share the NEW ERS Bronchiectasis Guidelines 2025!
Join us in Amsterdam #bronchiectasis #Guidelines
@AlibertiStefano @EMBARCnetwork
Diego J. Maselli MD, FCCP ATSF retweeted
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a... sciencedirect.com/science/ar… @BCMCME @BCM_Lung @BCMLungInst
Diego J. Maselli MD, FCCP ATSF retweeted
Just published online at @ERSpublications ERR
A deep dive into neutrophils and their role in bronchiectasis
An exciting new era with therapies targeting this treatable trait
2 subjects enrolled in 48 hours in the NEUTRALIZE AKI Trail!!! Great collaboration with Nephrology/Critical Care!! @BandakGhassan @UTHSA_PCCM @UTHealthSA
🔥🔥💪💪
Diego J. Maselli MD, FCCP ATSF retweeted
Management of #Asthma and #COPD Exacerbations in Adults in the ICU
Read the full research in the March issue of #journal_CHESTCritCare: hubs.la/Q03bNLd00
#JournalCHEST #CritCare #MedEd
Phenomenal Mecine Grand Rounds at UT Health San Antonio on Bronchiectasis by Dr Ashley Losier!! @AshleyLosierMD @UTHSA_PCCM @UTHealthSA @YaleMed
Diego J. Maselli MD, FCCP ATSF retweeted
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores - Respiratory Medicine resmedjournal.com/article/S0…
Great updates on bronchiectasis from Dr Meilinh Thi!! @UTHSA_PCCM
Fantastic talk by Dr. Estrada!! @REstradaMD Forum on Advances in Pulmonary Care @UTHSA_PCCM
Diego J. Maselli MD, FCCP ATSF retweeted
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials - The Lancet Respiratory Medicine thelancet.com/journals/lanre… @BCMLungInst @BCM_Lung
Phenomenal talks!! Join us on 3/1/2025. Free registration! @UTHSA_PCCM
cmetracker.net/UTHSCSA/Publi…
“The last bronchial thermoplasty” 🪦 The end of an era in severe asthma therapy? @UTHSA_PCCM
3
105































